Trikafta extends cystic fibrosis patients' lives, boosts Vertex's revenue

Summary: Vertex Pharmaceuticals' Trikafta can extend young cystic fibrosis patients' lives by up to 45 years, with a cost of $300,000 per patient annually in the US. Revenues doubled from $4.2bn to $8.9bn between 2019 and 2022. Trikafta has generated $26bn since 2019 and is expected to reach $10bn in annual sales. Vertex's non-opioid painkiller research and acquisitions aim to replicate its CF success.

Full article